Buscar
Johnson & Johnson
JNJAñadir a la lista de seguimiento
259.290USD
-3.750-1.43%
Cierre 07/06, 16:00（ET）Cotizaciones retrasadas 15 min
624.00BCap. mercado
29.67P/E TTM
Más Datos de Johnson & Johnson Compañía
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Información de Johnson & Johnson
Símbolo de cotizaciónJNJ
Nombre de la empresaJohnson & Johnson
Fecha de salida a bolsaOct 31, 2080
Director ejecutivoDuato (Joaquin Boix)
Número de empleados138100
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
DirecciónOne Johnson & Johnson Plaza
CiudadNEW BRUNSWICK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal08933
Teléfono17325242455
Sitio Webhttps://www.jnj.com/
Símbolo de cotizaciónJNJ
Fecha de salida a bolsaOct 31, 2080
Director ejecutivoDuato (Joaquin Boix)
Ejecutivos de Johnson & Johnson
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
--
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
24.91K
+57.22%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.00K
-2.57%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
19.83K
+28.80%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
--
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
24.91K
+57.22%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Johnson & Johnson?
Los cinco principales accionistas de Johnson & Johnson son: Mr. Joaquin Boix Duato
¿Cuántas instituciones poseen acciones de Johnson & Johnson (JNJ)?
A fecha de 2026Q1, 6338 instituciones poseen acciones de Johnson & Johnson, con un valor de mercado combinado de aproximadamente 1.78B, lo que representa el 73.80% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -65473493.00.
¿Cuál es la mayor fuente de ganancias de Johnson & Johnson?
El 2026Q1, el segmento empresarial Oncology-DARZALEX generó la ganancia más alta para Johnson & Johnson, ascendiendo a 14.35B y representando el 15.24% de la ganancia total.